Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006786 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006786: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00006786 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006786, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bevacizumab in treating patients who have advanced colorectal cancer.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- BIOLOGICAL bevacizumab
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00006786 record still lists
NCT00006786 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00006786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006786 about?
NCT00006786 is a clinical study titled "Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus bevac...
What is the current status of trial NCT00006786?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00006786?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), bevacizumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00006786?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia